{"schema_version":"secwatch.filing_event.v1","accession":"0001792044-22-000026","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.051019+00:00","generated_at":"2026-06-24T02:58:22.097760+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viatris Q2 2022: Revenue $4.12B, adj. EBITDA $1.48B, reaffirms guidance","bullets":["Total revenues $4.12B; U.S. GAAP net earnings $314M; adjusted EBITDA $1.48B.","Free cash flow $719M in Q2; H1 free cash flow ~$1.8B.","Reaffirms adjusted EBITDA and free cash flow guidance; revises total revenue guidance for FX.","Declares quarterly dividend $0.12 per share; paid down ~$1.5B debt in H1, on track for $2B full year.","Biocon Biologics transaction on track for H2 2022 close."],"urls":{"canonical":"https://secwatch.observer/filing/0001792044-22-000026","json":"https://secwatch.observer/filing/0001792044-22-000026.json","markdown":"https://secwatch.observer/filing/0001792044-22-000026.md","text":"https://secwatch.observer/filing/0001792044-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000179204422000026/0001792044-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000179204422000026/vtrs-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:58:22.097760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}